98%
921
2 minutes
20
DICER1 tumor predisposition syndrome results from pathogenic variants in DICER1 and is associated with a variety of benign and malignant lesions, typically involving kidney, lung, and female reproductive system. Over 70% of sarcomas in DICER1 tumor predisposition syndrome occur in females. Notably, pediatric cystic nephroma (pCN), a classic DICER1 tumor predisposition syndrome lesion, shows estrogen receptor (ER) expression in stromal cells. There are also renal, hepatic, and pancreatic lesions unassociated with DICER1 tumor predisposition syndrome that have an adult female predominance and are characterized/defined by ER-positive stromal cells. Except for pCN, the expression of ER in DICER1-associated lesions remains uninvestigated. In the present study, ER expression was assessed by immunohistochemistry in 89 cases of DICER1-related lesions and 44 lesions lacking DICER1 pathogenic variants. Expression was seen in stromal cells in pCN and pleuropulmonary blastoma (PPB) types I and Ir, whereas anaplastic sarcoma of kidney and PPB types II and III were typically negative, as were other solid tumors of non-Müllerian origin. ER expression was unrelated to the sex or age of the patient. Expression of ER showed an inverse relationship to preferentially expressed antigen in melanoma (PRAME) expression; as lesions progressed from cystic to solid (pCN/anaplastic sarcoma of kidney, and PPB types I to III), ER expression was lost and (PRAME) expression increased. Thus, in DICER1 tumor predisposition syndrome, there is no evidence that non-Müllerian tumors are hormonally driven and antiestrogen therapy is not predicted to be beneficial. Lesions not associated with DICER1 pathogenic variants also showed ER-positive stromal cells, including cystic pulmonary airway malformations, cystic renal dysplasia, and simple renal cysts in adult kidneys. ER expression in stromal cells is not a feature of DICER1 perturbation but rather is related to the presence of cystic components.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/PAS.0000000000002209 | DOI Listing |
Ann Med Surg (Lond)
September 2025
YunFu People's Hospital, Yunfu, China.
Introduction And Importance: Ovarian tumors are relatively rare in children and adolescent females, with mixed sex-cord-stromal tumors being a specific subtype that has a low incidence and is associated with DICER1 gene mutations.
Case Presentation: This case report describes a 14-year-old female patient diagnosed with a mixed sex-cord-stromal tumor associated with a DICER1 gene mutation, who had a rapid recurrence. The patient did not receive standardized chemotherapy after the initial surgery, and the tumor recurred within 6 months, leading to a second surgery and chemotherapy.
Endocr Pathol
September 2025
Department of Pathology, Medical Faculty, Institute of Molecular Pathology and Immunology (IPATIMUP), i3S-Institute for Research & Innovation in Health, University of Porto, Porto, 4200-135, Portugal.
Thyroid lesions associated with DICER1 syndrome include multifocal hyperplastic and benign neoplastic proliferations (follicular nodular disease) with characteristic macrofollicular and/or intrafollicular centripetal papillary growth patterns, frequently associated with atrophic and involutional changes. There are also well-differentiated thyroid carcinomas showing intermediate-type nuclei, sometimes combining high-grade areas (tumor-in-tumor pattern) and poorly differentiated carcinomas. Here, for the first time, we describe an encapsulated follicular cell thyroid tumor showing a mixed follicular and morular growth pattern, which presented in an 11-year-old girl with follicular nodular disease and a constitutional (germline) DICER1 p.
View Article and Find Full Text PDFRev Esp Patol
August 2025
Instituto Nacional de Neurología y Neurocirugía, Manuel Velasco Suárez, Secretaría de Salud, Mexico City (Ciudad de México), Mexico. Electronic address:
Introduction: Primary mesenchymal tumours of the central nervous system with uncertain differentiation are rare. The 5th edition of the WHO classification groups three of these entities according to their molecular profiles into: intracranial mesenchymal tumours with FET-CREB fusion, sarcomas with CIC rearrangement, and primary intracranial sarcomas with DICER1 mutations. The objectives of this study were to carry out a systematic review of the literature and to determine whether a specific morphology predominates in relation to the proposed molecular types.
View Article and Find Full Text PDFDiagn Cytopathol
October 2025
Division of Surgery, Department of Surgical Sciences, Faculty of Medicine and Health Sciences, University of Stellenbosch, Cape Town, South Africa.
Introduction: Thyroblastoma is a rare, aggressive thyroid neoplasm newly classified in the 2022 WHO Classification of Endocrine Tumors. It is characterized by embryonal, multilineage morphology and DICER1 mutations. Fewer than 15 well-characterized cases have been reported, with limited cytological descriptions.
View Article and Find Full Text PDFCurr Oncol
July 2025
Dipartimento di Medicina Clinica e Chirurgia, Scuola di Medicina e Chirurgia, Università degli Studi di Napoli Federico II, 80131 Napoli, Italy.
(1) Background: Sertoli-Leydig cell tumors (SLCTs) are rare ovarian neoplasms that account for less than 0.5% of all ovarian tumors. They usually affect young women and often present with androgenic symptoms.
View Article and Find Full Text PDF